OXFYY
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows the real-time analysis of DNA or RNA. It offers MinION Mk 1D, a portable device for DNA and RNA; GridION and GridION Q, a compact bench top device, which delivers a version of hard… Read more
OXFYY (OXFYY) - Net Assets
Latest net assets as of June 2025: $523.40 Million USD
Based on the latest financial reports, OXFYY (OXFYY) has net assets worth $523.40 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($671.70 Million) and total liabilities ($148.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $523.40 Million |
| % of Total Assets | 77.92% |
| Annual Growth Rate | 33.26% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 123.21 |
OXFYY - Net Assets Trend (2020–2024)
This chart illustrates how OXFYY's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OXFYY (2020–2024)
The table below shows the annual net assets of OXFYY from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $586.34 Million | -8.93% |
| 2023-12-31 | $643.85 Million | -7.17% |
| 2022-12-31 | $693.56 Million | -1.48% |
| 2021-12-31 | $703.98 Million | +278.62% |
| 2020-12-31 | $185.93 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OXFYY's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5706100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $988.30 Million | 168.55% |
| Total Equity | $586.34 Million | 100.00% |
OXFYY Competitors by Market Cap
The table below lists competitors of OXFYY ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genus plc
PINK:GENSY
|
$1.73 Billion |
|
JL MAG RARE-EARTH H YC1
F:3KLA
|
$1.73 Billion |
|
LIC Housing Finance Limited
NSE:LICHSGFIN
|
$1.73 Billion |
|
Wuxi Autowell Technology Co Ltd
SHG:688516
|
$1.73 Billion |
|
Permanent TSB Group Holdings PLC
LSE:PTSB
|
$1.72 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
$1.72 Billion |
|
Shanghai Tunnel Engineering Co Ltd
SHG:600820
|
$1.72 Billion |
|
Nippon Life India Asset Management Limited
NSE:NAM-INDIA
|
$1.72 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OXFYY's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 643,851,000 to 586,338,000, a change of -57,513,000 (-8.9%).
- Net loss of 146,188,000 reduced equity.
- New share issuances of 83,233,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-146.19 Million | -24.93% |
| Share Issuances | $83.23 Million | +14.2% |
| Other Changes | $5.44 Million | +0.93% |
| Total Change | $- | -8.93% |
Book Value vs Market Value Analysis
This analysis compares OXFYY's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 25.47x to 9.71x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.23 | $5.96 | x |
| 2021-12-31 | $0.86 | $5.96 | x |
| 2022-12-31 | $0.84 | $5.96 | x |
| 2023-12-31 | $0.75 | $5.96 | x |
| 2024-12-31 | $0.61 | $5.96 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OXFYY utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -79.80%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.27x
- Recent ROE (-24.93%) is below the historical average (-23.76%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -32.94% | -53.79% | 0.40x | 1.51x | $-79.84 Million |
| 2021 | -23.81% | -125.40% | 0.16x | 1.20x | $-238.01 Million |
| 2022 | -13.12% | -45.83% | 0.24x | 1.19x | $-160.38 Million |
| 2023 | -24.00% | -91.06% | 0.22x | 1.21x | $-218.89 Million |
| 2024 | -24.93% | -79.80% | 0.25x | 1.27x | $-204.82 Million |
Industry Comparison
This section compares OXFYY's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OXFYY (OXFYY) | $523.40 Million | -32.94% | 0.28x | $1.73 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |